Abstract
Nearly one half of the adult population in the U.S. experience some symptoms of insomnia (difficulties with getting to sleep, maintaining sleep, and/or sleep quality) on a weekly basis. Although most people with insomnia complain primarily of issues related to sleep maintenance and quality, current therapeutic approaches, including GABAA agonists, off label antidepressant use, H1 antagonists and melatonin agonists, primarily address sleep onset latency. The overall sleep architecture, especially that of the deeper stages of NREM sleep known as slow wave sleep (SWS), plays a crucial role in restorative, restful sleep. Through the 5-HT2A receptor, serotonin plays an active role in the regulation of sleep architecture. Antagonists / inverse-agonists of 5-HT2A, such as APD125, volinanserin, eplivanserin, pruvanserin and pimavanserin, are currently being investigated as therapeutics that could improve the treatment of sleep maintenance and quality in people with insomnia.
Keywords: Insomnia, sleep, serotonin, 5-HT2A, APD125, volinanserin, pruvanserin, eplivanserin, pimavanserin
Current Topics in Medicinal Chemistry
Title: 5-HT2A Inverse-Agonists for the Treatment of Insomnia
Volume: 8 Issue: 11
Author(s): Bradley R. Teegarden, Hussien Al Shamma and Yifeng Xiong
Affiliation:
Keywords: Insomnia, sleep, serotonin, 5-HT2A, APD125, volinanserin, pruvanserin, eplivanserin, pimavanserin
Abstract: Nearly one half of the adult population in the U.S. experience some symptoms of insomnia (difficulties with getting to sleep, maintaining sleep, and/or sleep quality) on a weekly basis. Although most people with insomnia complain primarily of issues related to sleep maintenance and quality, current therapeutic approaches, including GABAA agonists, off label antidepressant use, H1 antagonists and melatonin agonists, primarily address sleep onset latency. The overall sleep architecture, especially that of the deeper stages of NREM sleep known as slow wave sleep (SWS), plays a crucial role in restorative, restful sleep. Through the 5-HT2A receptor, serotonin plays an active role in the regulation of sleep architecture. Antagonists / inverse-agonists of 5-HT2A, such as APD125, volinanserin, eplivanserin, pruvanserin and pimavanserin, are currently being investigated as therapeutics that could improve the treatment of sleep maintenance and quality in people with insomnia.
Export Options
About this article
Cite this article as:
Teegarden R. Bradley, Shamma Al Hussien and Xiong Yifeng, 5-HT2A Inverse-Agonists for the Treatment of Insomnia, Current Topics in Medicinal Chemistry 2008; 8 (11) . https://dx.doi.org/10.2174/156802608784936700
DOI https://dx.doi.org/10.2174/156802608784936700 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Medico-Legal Evaluation of Fatal Perinatal Asphyxia
Current Pediatric Reviews The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design PREFACE: “The Lower the Better” Association between White-coat Effect-excluded Blood Pressure and Cardiovascular Events in High-risk Hypertension: Insights from SPRINT
Current Hypertension Reviews Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs
Current Drug Delivery Renal Complications of Fabry Disease
Current Pharmaceutical Design Usefulness of Real-Time PCR for the Diagnosis of Sepsis in ICU-Acquired Infections
Infectious Disorders - Drug Targets Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Effects of Peroxyl Radicals on Contractility of Rabbit Aorta and Guinea Pig Atria
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Pharmacogenomics and Severe Infections: The Role of the Genomes of Both the Host and the Pathogen
Current Pharmacogenomics Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands
Mini-Reviews in Medicinal Chemistry High Blood Pressure and the Risk of Stroke
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Vicious Cycles Within the Neuropathophysiologic Mechanisms of Alzheimers Disease
Current Alzheimer Research